ADVFN - Advanced Financial Network.
HOME» AMEX » P » PLX Stock Price » PLX Stock News

Protalix Biotherapeutics Share News

 Protalix Biotherapeutics, Stock Price
PLX Stock Price
 Protalix Biotherapeutics, Stock Chart
PLX Stock Chart
 Protalix Biotherapeutics, Stock News
PLX Stock News
 Protalix Biotherapeutics, Company Information
PLX Company Information
 Protalix Biotherapeutics, Stock Trades
PLX Stock Trades

Protalix Gets $25 Million Milestone Payment For Rare-Disease Drug

By Kristin Jones Protalix BioTherapeutics Inc. (PLX) has received a $25 million milestone payment from Pfizer Inc. (PFE) after the U.S. Food and Drug Administration approved its new drug for the treatment of Gaucher disease. On May 1, U.S. regulators approved taliglucerase alfa, sold as Elelyso, for the treatment of type 1 Gaucher disease, a genetic disorder that can cause enlargement of the spleen and liver, as well as lung disease and bone problems. Pfizer and Protaliz entered an exclusive agreement for the development and commercialization of Elelyso in November 2009. Under the terms of the deal, Pfizer has an exclusive license to sell Elelyso, except in Israel. Elelyso, an infusion administered by health-care professionals every other week, is the first plant-derived cell-based enzyme replacement. It will compete in the U.S. with the Gaucher-disease treatment Cerezyme, produced by Genzyme, the U.S. biotechnology unit of Sanofi S.A. (SNY, SAN.FR) and Shire PLC's (SHPGY, SHP.LN) Vpriv. Protalix shares rose 2.4% to $6.85 in premarket trading. The stock is up 36% so far this year. Write to Kristin Jones at

Stock News for Protalix Biotherapeutics (PLX)
01/04/201616:31:56Current Report Filing (8-k)
12/21/201506:01:39Notice of Effectiveness (effect)
12/15/201510:13:07Confidential Treatment Order (ct Order)
12/15/201507:31:59Statement of Changes in Beneficial Ownership (4)
12/11/201516:35:07Amended Quarterly Report (10-q/a)
11/27/201513:16:49Securities Registration Statement (simplified Form) (s-3/a)
11/23/201516:50:30Statement of Ownership (sc 13g)
11/23/201516:07:08Current Report Filing (8-k)
11/16/201507:16:13Current Report Filing (8-k)
11/16/201507:00:00Protalix BioTherapeutics to Conduct Phase III Clinical Trial...
11/13/201516:07:49Securities Registration Statement (simplified Form) (s-3)
11/10/201513:12:26Amended Statement of Ownership (sc 13g/a)
11/09/201517:41:48Quarterly Report (10-q)
11/09/201516:18:25Current Report Filing (8-k)
11/09/201516:05:00Protalix BioTherapeutics Reports Third Quarter 2015 Financial...
10/26/201507:31:18Additional Proxy Soliciting Materials (definitive) (defa14a)
10/23/201515:47:53Statement of Ownership (sc 13g)
10/23/201511:09:13Amended Statement of Ownership (sc 13g/a)
10/20/201513:51:34Initial Statement of Beneficial Ownership (3)
10/19/201507:35:33Current Report Filing (8-k)

Protalix Biotherapeutics and other American Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations